Charles River Laboratories International, Inc. (NYSE:CRL) received a $117.00 price target from research analysts at Robert W. Baird in a report released on Monday. The brokerage presently has a “buy” rating on the medical research company’s stock. Robert W. Baird’s target price suggests a potential upside of 14.78% from the company’s previous close.

A number of other equities analysts have also recently weighed in on CRL. ValuEngine cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday. Bank of America Corporation dropped their price target on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday. Zacks Investment Research cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Finally, Jefferies Group LLC restated a “buy” rating and set a $120.00 price objective on shares of Charles River Laboratories International in a research report on Tuesday, September 12th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Charles River Laboratories International presently has an average rating of “Buy” and an average price target of $106.05.

Charles River Laboratories International (CRL) opened at $101.93 on Monday. The firm has a market capitalization of $4,836.56, a PE ratio of 20.06, a P/E/G ratio of 1.63 and a beta of 0.94. Charles River Laboratories International has a 12 month low of $69.51 and a 12 month high of $119.05. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. The firm had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. Charles River Laboratories International’s revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. analysts expect that Charles River Laboratories International will post 5.12 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Given a $117.00 Price Target at Robert W. Baird” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/charles-river-laboratories-internationals-crl-buy-rating-reaffirmed-at-robert-w-baird/1700985.html.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories International stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $0.27, for a total transaction of $270,000.00. Also, insider Davide Molho sold 5,982 shares of Charles River Laboratories International stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total value of $643,364.10. Following the sale, the insider now owns 22,714 shares of the company’s stock, valued at $2,442,890.70. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 10,500 shares of company stock valued at $2,885 and have sold 1,016,147 shares valued at $1,991,154. 2.20% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the company. YorkBridge Wealth Partners LLC lifted its holdings in shares of Charles River Laboratories International by 445.5% during the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after buying an additional 891 shares during the last quarter. Advisor Group Inc. lifted its holdings in Charles River Laboratories International by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after purchasing an additional 945 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Charles River Laboratories International by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after purchasing an additional 202 shares during the last quarter. Riverhead Capital Management LLC lifted its holdings in Charles River Laboratories International by 14.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares during the last quarter. Finally, Cambridge Advisors Inc. acquired a new stake in Charles River Laboratories International in the 2nd quarter worth approximately $202,000. Institutional investors and hedge funds own 97.46% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.